

**EUROPEAN
CURRICULUM VITAE
FORMAT**



PERSONAL INFORMATION

Name Tagliabue Elda
Address
Telephone
Fax
E-mail
Nationality Italian
Date of birth 23th September 1955

WORK EXPERIENCE

- Dates (from – to) February 1, 2023 – to date
- Name and address of employer Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- Type of business or sector Translational Oncology
- Occupation or position held Professional Collaborator
- Main activities and responsibilities Scientific and organizational coordination of a cross-disciplinary project aimed at identifying new prognostic tumor biomarkers

- Dates (from – to) January 1, 2009 – January 3, 2023
- Name and address of employer Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- Type of business or sector Experimental Oncology
- Occupation or position held Head of Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine
- Main activities and responsibilities Managerial and scientific coordination of a research group

- Dates (from – to) 1998-2008
- Name and address of employer Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- Type of business or sector Experimental Oncology
- Occupation or position held Staff Scientist, Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine
- Main activities and responsibilities Coordinator of the research group studying the molecular characteristics of breast carcinomas and their response to chemo and targeted therapies

- Dates (from – to) 1991-1998
- Name and address of employer Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- Type of business or sector Experimental Oncology
- Occupation or position held Staff Scientist, Division of Experimental Oncology E
- Main activities and responsibilities Designing and executing experiments in the field of HER2-targeted therapies

- Dates (from – to) 1985-1991
- Name and address of employer Fondazione IRCCS 'Istituto Nazionale dei Tumori', Milan, Italy
- Type of business or sector Experimental Oncology
- Occupation or position held Research Associate (permanent position), Division of Experimental Oncology E
- Main activities and responsibilities Production of monoclonal antibodies and molecular characterization of HER2-overexpressing breast carcinoma

- Dates (from – to)
- Name and address of employer
 - Type of business or sector
 - Occupation or position held
- Main activities and responsibilities

EDUCATION AND TRAINING

- Dates (from – to)
- Name and type of organisation providing education and training
- Principal subjects/occupational skills covered
 - Title of qualification awarded
 - Level in national classification (if appropriate)

- Dates (from – to)
- Name and type of organisation providing education and training
- Principal subjects/occupational skills covered
 - Title of qualification awarded
 - Level in national classification (if appropriate)

- Dates (from – to)
- Name and type of organisation providing education and training
- Principal subjects/occupational skills covered
 - Title of qualification awarded
 - Level in national classification (if appropriate)

PERSONAL SKILLS AND COMPETENCES

Acquired in the course of life and career but not necessarily covered by formal certificates and diplomas

MOTHER TONGUE

OTHER LANGUAGES

- Reading skills
- Writing skills
- Verbal skills

SOCIAL SKILLS AND COMPETENCES

Living and working with other people, in multicultural

1983-1985

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Experimental Oncology

Research Associate, Division of Experimental Oncology A

Designing and executing experiments in the field of tumor immunology, production of monoclonal antibody directed against tumor associated antigens

1979-1982

Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

PHD student Division Experimental Oncology A

PhD in Biological Sciences

1974-1978

University of Milan

Degree in Biological Science

1969-1974

High School, Milan

Classical Studies

Baccalaureate

ITALIAN

ENGLISH

GOOD

GOOD

GOOD

Editorial Boards

-Member of the Editorial Board of Chinese Journal of Clinicians

-Member of the Editorial Board of International Journal of Biological Markers

environments, in positions where communication is important and situations where teamwork is essential (for example culture and sports), etc.

- Member of the Editorial Board of Journal of Solid Tumors
- Member of the Editorial Board of PLoS One
- Barts and the London Charity
- Irish Health Research Board

Peer-Review Research Evaluation of National (AIRC and MIUR)) and international programs (ERC, Dutch Cancer Society, Institut National du Cancer and Irish Health Research Board, CanServ).

Ad Hoc reviewer for: Annals of Oncology, BC Research, BC Research and Treatment, British Journal of Cancer, Cancer Detection and Prevention, Cancer Research, European Journal of Cancer, International Journal of Cancer, Journal of Cellular Physiology, The Oncologist, Oncogene and Tumor Biology.

Scientific associations

National

- Italian Society of Cancerology (SIC)

International

- American Association for Cancer Research (AACR)
- International Cancer Microenvironment Society (ICMS)
- European Association for Cancer Research (EACR)
- European Academy of Tumor Immunology (EATI)

Board Member of the Italian Society of Cancerology (SIC) from 2013 to 2019.

Sponsored by Italian Ministry of Health, European Community and AIRC (Italian Association for Cancer Research).

Dr Tagliabue counts numerous invitations to national and international conferences. She is and has been responsible for several projects funded by AIRC; Italy-USA Program on Cancer Research; Cariplo Foundation, MIUR and Alliance Against Cancer.

Throughout her career, Dr. Elda Tagliabue has been involved in both clinical and pre-clinical research addressing the role of HER2 oncoprotein and receptors for adhesion molecules in breast cancer tumorigenesis, progression and response to therapy. This work has produced more than 250 publications in peer-reviewed journals —data according to Scopus: total number of citations:14,030; H index: 63— and 21 co-authored books. Dr. Tagliabue furthered her scientific experience through collaborations and additional training periods in internationally recognized laboratories such as the Metastasis Laboratory of Liege University and The Weizmann Institute of Science of Rehovot, Israel, where she focused on the purification of adhesion molecule receptors and on the function of growth factor receptors, respectively. By addressing the role of HER2 oncoprotein in breast cancer tumorigenesis and progression, Dr. Tagliabue showed for the first time that HER2 overexpression plays a role in post-surgery stimulation of growth of breast carcinoma cells (Lancet 2003), shedding light on the mechanism involved in the early relapse which characterizes these patients. In 2004, she contributed to the demonstration that trastuzumab can mediate ADCC in HER2-positive breast carcinoma patients (Clin Cancer Res 2004), leading the way toward in-depth analysis of host immune system responsibility for trastuzumab efficacy and currently followed by several groups involved in optimization of HER2-targeted therapies. In the last years, Dr. Tagliabue's expertise in translational research has contributed greatly in accomplishing three different observational studies on the role of HER2 in tumor progression and trastuzumab activity in the Italian clinical practice, all supported by Roche and successfully published in the relevant journals. Very recently, her team identified a new molecular classifier predictive of adjuvant trastuzumab benefit (Oncotarget 2015) and discovered a mechanism through which chemotherapy could maximize the antibody effect (Oncotarget 2016). In 2018, Dr. Tagliabue demonstrated that HER2 signaling directly influences the recruitment of immune cells regulating the tumor immune microenvironment and trastuzumab efficacy (*Onc Immunology* 2019).

Concerning the study of tumor/stroma interaction, Dr. Tagliabue strongly contributed to shed light on the mechanism by which the monomeric laminin receptor plays a major role in tumor aggressiveness and metastasis (*Cancer Res* 2002). In collaboration with the Department of Genetics at the Norwegian Radium Hospital in Oslo, she demonstrated that breast carcinomas can be sub grouped according to extracellular matrix features (J of Pathol 2008), paving the way for analysis of extracellular matrix significance in breast cancer progression.

Consequently, Dr. Tagliabue's group found that differential expression of ECM genes delineates a robust cluster that identifies breast carcinomas with EMT features but with accelerated metastatic potential only in the undifferentiated phenotype (PLoS One 2013) and so opening a discussion on the clinical relevance of stromal signatures. In 2016, she contributed to the demonstration that mesenchymal transition of high-grade breast carcinomas depends on extracellular matrix control of myeloid suppressor cell activity (Cell Rep. 2016).

In 2018 she awarded a Grant AIRC aimed at understanding the contribution of gut microbiota in trastuzumab activity to improve drug responsiveness. During this study, she demonstrated that gut microbiota has a role in efficacy of trastuzumab (*Cancer Res* 2021) gut ecosystem modification as a tool to optimize anti-HER2 therapies. In collaboration with the University of Milan she also contributed to shed light on breast microbiota in cancer progression and response to therapy.

From 2023 she coordinates an institutional cross-disciplinary project aimed at investigating whether microbiota present in different type of tumors may be involved in disease progression and response to therapy.

Mentoring activity of Dr. Tagliabue led to numerous Bachelors and Master of Science graduates. Concerning Doctors in Philosophy, she examined 10 UK and 7 non-UK PhD students and successfully supervised 8 UK PhD students. Among her PhD students, one with an exceptional propensity for the research field has been awarded an AIRC start-up grant for the study of miRNAs in breast cancer progression and response to targeted therapies. More than 10 monoclonal antibodies produced by Dr. Tagliabue's team are now commercially available and abroad used for research.

ORGANISATIONAL SKILLS AND COMPETENCES

Coordination and administration of people, projects and budgets; at work, in voluntary work (for example culture and sports) and at home, etc.

Good communication skills gained through experience as responsible of a research team. Currently responsible for a team of 20 researchers involved in the translational research of breast carcinoma

TECHNICAL SKILLS AND COMPETENCES

With computers, specific kinds of equipment, machinery, etc.

Good command of cell culture, transfection, Western blot, immunoprecipitation, protein and nucleic acid purification, cytofluorimetric analysis, immunohistochemistry, qPCR, somatic fusion and selection of monoclonal antibodies

Design of laboratory experiments, discussion and interpretation of obtained results, planning of new research projects, writing of scientific papers and grants. Good command of Microsoft Office™ tools

ARTISTIC SKILLS AND COMPETENCES

Music, writing, design, etc.

OTHER SKILLS AND COMPETENCES

Competences not mentioned above.

DRIVING LICENCE(S)

Car driving

La sottoscritta è a conoscenza che, ai sensi dell'art.76 DPR 28/12/2000 n.445, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto, ai sensi della vigente normativa nazionale ed europea in tema di protezione dei dati personali, in particolare del Regolamento UE 2016/679, autorizza la Fondazione IRCCS Istituto Nazionale dei Tumori di Milano al trattamento dei dati personali per l'espletamento delle attività necessarie alla realizzazione di attività formative, accreditate ECM e non, e inserite nel piano di formazione dello stesso Istituto".

Milan, January 20, 2025

Elda Tagliabue